Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory randomized double-blind study of two oral pantoprazole doses for maintenance therapy of healed erosive esophagitis in pediatric participants
2020-005030-15Phase 2Active
- Sponsor
- Pfizer
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pantoprazole in erosive esophagitis (EE) (2 arms), sponsored by Pfizer. Primary endpoint: Maintenance of healing of erosive esophagitis at Week 24. Started May 2021; status: active.
02
Drugs
pantoprazole
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on 2020-005030-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005030-15.